Loading
Antitumour Efficacy / Astragali Radix-curcumae Rhizoma Pair-derived Exosome-like Nanoparticles · Journal article
International Journal of Pharmaceutics: X · July 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
Exosome-like nanoparticles derived from Astragali Radix-Curcumae Rhizoma co-decoction improved oral bioavailability of herbal bioactive components in cellular and rat studies. When combined with 5-fluorouracil in a Lewis lung cancer mouse model, the nanoparticles demonstrated superior antitumour efficacy and excellent biocompatibility compared to controls.
Preclinical study with cellular assays, rat pharmacokinetics, and mouse xenograft model. Cellular studies, rats for pharmacokinetic assessment, and Lewis lung cancer ectopic mouse model for efficacy evaluation. Intervention: Exosome-like nanoparticles derived from Astragali Radix-Curcumae Rhizoma co-decoction combined with 5-fluorouracil.
ACELNs significantly improved oral bioavailability of loaded active components in cellular and rat pharmacokinetic studies Combination of ACELNs and 5-FU exhibited superior antitumour efficacy in Lewis lung cancer ectopic mouse model ACELNs maintained excellent structural integrity, flat spheroid morphology, and favorable gastrointestinal stability
Lack of specific toxicity measurements or comparator arm definitions ACELNs significantly improved oral bioavailability of loaded active components in cellular and rat pharmacokinetic studies
This preclinical study suggests a potential strategy to overcome bioavailability limitations of traditional Chinese medicine components and enhance chemotherapy efficacy while reducing toxicity. Translation to clinical practice requires human pharmacokinetic, safety, and efficacy studies.
Preclinical mouse model data showing enhanced bioavailability and synergistic efficacy; no human safety or efficacy data yet available.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical study suggests a potential strategy to overcome bioavailability limitations of traditional Chinese medicine components and enhance chemotherapy efficacy while reducing toxicity. Translation to clinical practice requires human pharmacokinetic, safety, and efficacy studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The low oral bioavailability of bioactive components from the Astragali Radix-Curcumae Rhizoma herb pair severely restricts its clinical application in antitumour therapy. To address this issue, we developed a natural drug delivery system using exosome-like nanoparticles (ACELNs) isolated from the co-decoction of Astragali Radix and Curcumae Rhizoma, which can effectively encapsulate and preserve the bioactive components from the herbal pair. Systematic characterization confirmed that ACELNs maintained excellent structural integrity, flat spheroid morphology, and favorable gastrointestinal stability with desirable colloidal properties. Cellular and rat pharmacokinetic studies demonstrated that ACELNs significantly improved the oral bioavailability of the loaded active components. In Lewis lung cancer ectopic mouse model, the combination of ACELNs and 5-fluorouracil (5-FU) exhibited superior antitumour efficacy and excellent biocompatibility. This natural nanocarrier strategy provides a promising approach to overcome the bioavailability barrier of traditional Chinese medicine components and achieve synergistic therapeutic effects.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.